Cancer Clinical Trials Information Platform in Hong Kong

  1. This serves merely as an information platform about cancer clinical trials operated by different institutions in Hong Kong. HKACS is not responsible for the contents, availability and operability of the trials listed.
  2. Respective institutions usually reserve all rights regarding the implementation and execution of their respective clinical trials.
  3. Patients usually need to satisfy a complex and stringent set of selection criteria before being selected/ included in certain clinical trials. Interested parties should contact respective institutions regarding further details of the trials

Cancer Site

*in alphabetical order (Last updated on 10/8/2017)

Prostate Cancer

Institution Study Title  
CUHK A randomized, open label, phase II study: stereotactic body radiotherapy (SBRT) vs conventional intensity-modulated radiotherapy (IMRT) for low or intermediate risk prostate cancer in Asia population Click for Details
CUHK Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199) Click for Details
HKU A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, Versus Enzalutamide Alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone Closed
PYNEH Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial [RTOG 0924] Click for Details
QMH A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of Masitinib in combination with Docetaxel to placebo in combination with Docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC) Click for Details
*institution arranged in alphabetical order

For Enquiry, please contact the respective institute, HKACS is not responsible for the outcomes of the clinical trials.